Inotuzumab ozogamicin linked to better outcomes than standard chemotherapy for ALL: The INO-VATE ALL trial
1. Inotuzumab ozogamaxin (IO) demonstrated significantly higher complete remission rates and median progression-free survival compared to standard chemotherapy in relapsed...


![Adverse pregnancy outcomes associated with thrombophilias [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2015/07/Classics-2-Minute-Medicine-e1436017941513-350x250.png)




![Reduced neuronal BRCA1 associated with decreased DNA repair in Alzheimer’s disease [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2015/12/DNA_Furchen_edited-350x250.png)

